Jun 02, 2021 / 05:00PM GMT
Brandon Couillard - Jefferies LLC, Research Division - Equity Analyst
Good afternoon. Thanks, everybody, for joining us. Welcome to the Jefferies 2021 Virtual Global Healthcare Conference. I'm Brandon Couillard. I cover the life science tools and diagnostics sector here at the firm. Very pleased to have Danaher with us at the conference this year and joining us for this fireside conversation, CFO, Matt McGrew; and also have Head of IR, Matt Gugino, with us. So thank you both for being here.
Questions and Answers:
Brandon Couillard - Jefferies LLC, Research Division - Equity AnalystMatt, wanted to start off with what, I think, is certainly top of mind for investors right now, especially coming out of Abbott's updated guidance yesterday around COVID testing. So want to start with Cepheid. You guys have been pretty upbeat about your PCR testing outlook, talking about Cepheid volumes going from 10 million in the first quarter to 13 million by the end of the year. So kind of 45 million tests for '21. And a similar number, you kind of endorsed for '22. Can you